Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen.

8 Oct 2016

Researchers to explore potential roles of tumor-suppressor gene in kidney cancer

Renal cell carcinoma is the most common type of kidney cancer, and African-Americans and males appear most at risk for this disease that can be asymptomatic until it has spread and become highly lethal, said Dr. Vinata B. Lokeshwar, cancer researcher and chair of the Department of Biochemistry and Molecular Biology at the Medical College of Georgia at Augusta University.

7 Oct 2016

Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in Copenhagen.

7 Oct 2016

New study highlights need for routine skin cancer screening for all transplant patients

A new study from Drexel University College of Medicine suggests all organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer.

7 Oct 2016

IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

Radiation therapy is the main treatment modality in the management of head and neck cancer.

4 Oct 2016

Ki67 may help spare some breast cancer patients from sentinel lymph node biopsies

Breast cancer patients over 50 years old could be spared invasive procedures by use of stratification based on tumour size and molecular characteristics, including Ki67.

29 Sep 2016

Radiation boost provides added benefit to DCIS patients following breast-conserving surgery and WBRT

A supplemental "boost" of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.

27 Sep 2016

Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology.

27 Sep 2016

$Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients$

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.

26 Sep 2016

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

A new analysis of records in the Veteran's Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.

26 Sep 2016

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease.

26 Sep 2016

Study finds nonwhite transplant recipients at risk for skin cancer

A new study from Drexel University College of Medicine suggests all organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer.

21 Sep 2016

Tumor microenvironment acts as source of resistance to cancer therapies

Researchers at Bellvitge Biomedical Research Institute have published a new Oncotarget work which highlights the importance of the tumor environment as a source of resistance to treatment in colorectal cancer, the fourth most common cancer and the leading cause of cancer death worldwide.

7 Sep 2016

Overweight kidney cancer patients live longer than normal-weight counterparts, study shows

Obesity almost always increases cancer risk and worsens outcomes, but researchers led by scientists at Dana-Farber Cancer Institute report that overweight patients with advanced kidney cancer had significantly longer survival than those who were normal or underweight.

6 Sep 2016

HIF-2 inhibitors could be promising target to combat kidney cancer

A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found.

6 Sep 2016

Selenium status linked to cancer risk

As a nutritional trace element, selenium forms an essential part of our diet. In collaboration with the International Agency for Research on Cancer, researchers from Charité - Universitätsmedizin Berlin have been able to show that high blood selenium levels are associated with a decreased risk of developing liver cancer.

31 Aug 2016

Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2016 and updates on its drug development programs.

27 Aug 2016

Carcinoma News and Research

Further Reading

Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

Researchers to explore potential roles of tumor-suppressor gene in kidney cancer

Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

New study highlights need for routine skin cancer screening for all transplant patients

IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

Ki67 may help spare some breast cancer patients from sentinel lymph node biopsies

Radiation boost provides added benefit to DCIS patients following breast-conserving surgery and WBRT

Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

Study finds nonwhite transplant recipients at risk for skin cancer

Tumor microenvironment acts as source of resistance to cancer therapies

Overweight kidney cancer patients live longer than normal-weight counterparts, study shows

HIF-2 inhibitors could be promising target to combat kidney cancer

Selenium status linked to cancer risk

Can-Fite BioPharma reports financial results, provides update on drug development programs

Low selenium levels linked to liver cancer risk? An interview with Dr David Hughes

Added benefit of lung cancer drug not proven, says IQWiG

Computers could be more accurate than pathologists in assessing lung cancer tissues, study shows

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News